Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + anlotinib in previously treated advanced NSCLC after PD-1/PD-L1 resistance
ChiCTR2500096724Phase 2Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Feb 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective response rate. Started Feb 2025; status: recruiting.
02
Drugs
cadonilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500096724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096724.